BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
BC Week In Review | Sep 26, 2016
Clinical News

Chenodeoxycholic acid regulatory update

EMA’s CHMP recommended approval of chenodeoxycholic acid from Sigma-Tau to treat cerebrotendinous xanthomatosis. The naturally occurring bile acid is approved as Xenbilox in the EU to treat gall stones. Sigma-Tau Group , Pomezia, Italy   Product:...
BC Week In Review | Apr 18, 2016
Financial News

Fennec Pharmaceuticals completes private placement

Fennec Pharmaceuticals Inc. (TSX:FRX), Research Triangle Park, N.C.   Business: Cancer, Other   Date completed: 2016-04-08   Type: Private placement   Raised: $2.1 million   Shares: 1.1 million   Price: $1.90   Shares after offering:...
BC Innovations | Feb 4, 2016
Distillery Therapeutics

Therapeutics: Farnesoid X receptor (FXR; NR1H4)

Autoimmune disease INDICATION: Multiple sclerosis (MS) Mouse studies suggest FXR agonists could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, the endogenous FXR ligand chenodeoxycholic acid or the FXR agonist...
BC Week In Review | Jan 25, 2016
Clinical News

Oncaspar pegaspargase regulatory update

The European Commission approved an MAA from Baxalta for Oncaspar pegaspargase to treat acute lymphoblastic leukemia (ALL) in patients of all ages in combination with antineoplastic therapy. In November, EMA’s CHMP recommended the approval. In...
BC Extra | Jan 5, 2016
Company News

Baxalta, Symphogen in immuno-oncology deal

Baxalta Inc. (NYSE:BXLT) and Symphogen A/S (Copenhagen, Denmark) partnered to develop cancer therapeutics against six undisclosed checkpoint targets. The deal is Baxalta's largest in cancer since its spinout from Baxter International Inc. (NYSE:BAX) last year....
BC Week In Review | Dec 7, 2015
Clinical News

Oncaspar pegaspargase regulatory update

EMA’s CHMP recommended approval of Oncaspar pegaspargase from Baxalta to treat acute lymphoblastic leukemia (ALL) in patients of all ages in combination with antineoplastic therapy. In July, Baxalta purchased the pegylated L-asparaginase enzyme from Sigma-Tau...
BC Week In Review | Aug 17, 2015
Company News

Sigma-Tau, Pierre Fabre Group deal

Sigma-Tau granted Pierre Fabre an exclusive license to commercialize Eurartesim in 32 African countries. The antimalarial combination of dihydroartemisinin and piperaquine is approved in Europe and several of the countries covered by the deal. Pierre...
BioCentury | Jul 13, 2015
Strategy

Baxalta's blueprint

Now that Baxalta Inc. has completed its spinout from Baxter International Inc. , the newco's ambitious plan is to launch 20 new drugs, including line extensions, by 2020. The products, which come from a mix of...
BC Week In Review | May 18, 2015
Company News

Sigma-Tau, Baxter deal

Baxter will purchase a portfolio of leukemia products from Sigma-Tau’s Sigma-Tau Finanziaria S.p.A. unit for $900 million. The portfolio includes Oncaspar pegasparagase, which is marketed to treat acute lymphoblastic leukemia (ALL), and calaspargase pegol, a...
Items per page:
1 - 10 of 228
BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
BC Week In Review | Sep 26, 2016
Clinical News

Chenodeoxycholic acid regulatory update

EMA’s CHMP recommended approval of chenodeoxycholic acid from Sigma-Tau to treat cerebrotendinous xanthomatosis. The naturally occurring bile acid is approved as Xenbilox in the EU to treat gall stones. Sigma-Tau Group , Pomezia, Italy   Product:...
BC Week In Review | Apr 18, 2016
Financial News

Fennec Pharmaceuticals completes private placement

Fennec Pharmaceuticals Inc. (TSX:FRX), Research Triangle Park, N.C.   Business: Cancer, Other   Date completed: 2016-04-08   Type: Private placement   Raised: $2.1 million   Shares: 1.1 million   Price: $1.90   Shares after offering:...
BC Innovations | Feb 4, 2016
Distillery Therapeutics

Therapeutics: Farnesoid X receptor (FXR; NR1H4)

Autoimmune disease INDICATION: Multiple sclerosis (MS) Mouse studies suggest FXR agonists could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, the endogenous FXR ligand chenodeoxycholic acid or the FXR agonist...
BC Week In Review | Jan 25, 2016
Clinical News

Oncaspar pegaspargase regulatory update

The European Commission approved an MAA from Baxalta for Oncaspar pegaspargase to treat acute lymphoblastic leukemia (ALL) in patients of all ages in combination with antineoplastic therapy. In November, EMA’s CHMP recommended the approval. In...
BC Extra | Jan 5, 2016
Company News

Baxalta, Symphogen in immuno-oncology deal

Baxalta Inc. (NYSE:BXLT) and Symphogen A/S (Copenhagen, Denmark) partnered to develop cancer therapeutics against six undisclosed checkpoint targets. The deal is Baxalta's largest in cancer since its spinout from Baxter International Inc. (NYSE:BAX) last year....
BC Week In Review | Dec 7, 2015
Clinical News

Oncaspar pegaspargase regulatory update

EMA’s CHMP recommended approval of Oncaspar pegaspargase from Baxalta to treat acute lymphoblastic leukemia (ALL) in patients of all ages in combination with antineoplastic therapy. In July, Baxalta purchased the pegylated L-asparaginase enzyme from Sigma-Tau...
BC Week In Review | Aug 17, 2015
Company News

Sigma-Tau, Pierre Fabre Group deal

Sigma-Tau granted Pierre Fabre an exclusive license to commercialize Eurartesim in 32 African countries. The antimalarial combination of dihydroartemisinin and piperaquine is approved in Europe and several of the countries covered by the deal. Pierre...
BioCentury | Jul 13, 2015
Strategy

Baxalta's blueprint

Now that Baxalta Inc. has completed its spinout from Baxter International Inc. , the newco's ambitious plan is to launch 20 new drugs, including line extensions, by 2020. The products, which come from a mix of...
BC Week In Review | May 18, 2015
Company News

Sigma-Tau, Baxter deal

Baxter will purchase a portfolio of leukemia products from Sigma-Tau’s Sigma-Tau Finanziaria S.p.A. unit for $900 million. The portfolio includes Oncaspar pegasparagase, which is marketed to treat acute lymphoblastic leukemia (ALL), and calaspargase pegol, a...
Items per page:
1 - 10 of 228